Huntington's disease is an inherited disease that causes degeneration of nerve cells in the central nervous system (CNS). The disease has a broad impact on functional abilities of the human and usually results in movement and thinking disabilities. Most people with Huntington's disease develop signs and symptoms in their age of 30 to 40. When disease begins before age 20, the condition is known as juvenile Huntington's disease.
The demand for Huntington’s disease (HD) therapeutics as one of the primary growth factors for the Huntington’s disease therapeutics market. HD is equally prevalent in both males and females and affects people irrespective of their ethnicity. The disease symptoms may appear anytime in the individual’s life and the etiology is genetic. The person who inherits the mutated genes from their affected parents will probably suffer from the disease sometime in their lifetime.
The Americas is witnessing increasing incidences of HD. The availability of increased patient pool and the rise in government initiatives boost the research and development of novel therapeutics for the treatment of HD. The rising investments towards the launch of new drugs for the treatment of chorea will positively influence the growth of the Huntington’s disease therapeutics market in this region.
The global Huntington's Disease Therapeutics market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Huntington's Disease Therapeutics market based on company, product type, end user and key regions.
This report studies the global market size of Huntington's Disease Therapeutics in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Huntington's Disease Therapeutics in these regions.
This research report categorizes the global Huntington's Disease Therapeutics market by top players/brands, region, type and end user. This report also studies the global Huntington's Disease Therapeutics market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
F. Hoffmann-La Roche
Teva Pharmaceutical Industries
Market size by Product
Market size by End User
Market size by Region
Central & South America
Rest of Central & South America
Middle East & Africa
The study objectives of this report are:
To study and analyze the global Huntington's Disease Therapeutics market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Huntington's Disease Therapeutics market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Huntington's Disease Therapeutics companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Huntington's Disease Therapeutics submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Huntington's Disease Therapeutics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Huntington's Disease Therapeutics market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.